zacopride

Also Known As:

4-amino-5-iodo-2-methoxy-N-(1-azabicyclo(2.2.2)oct-3-yl)benzamide; 4-amino-N-(1-azabicyclo(2,2,2)oct-3-yl)-5-chloro-2-methoxybenzamide-2-butenedioate; iodozacopride; zacopride hydrochloride

Networked: 49 relevant articles (7 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cao, Ji-Min: 6 articles (01/2021 - 01/2012)
2.	Wu, Bo-Wei: 6 articles (01/2021 - 01/2012)
3.	Liu, Qing-Hua: 5 articles (01/2021 - 01/2012)
4.	Zhang, Li: 4 articles (12/2019 - 10/2014)
5.	Cao, Jimin: 3 articles (01/2021 - 12/2019)
6.	Liu, Qinghua: 3 articles (01/2021 - 12/2019)
7.	Wu, Bowei: 3 articles (01/2021 - 12/2019)
8.	Feng, Qi-Long: 3 articles (01/2019 - 10/2014)
9.	Zhai, Xu-Wen: 3 articles (01/2019 - 10/2014)
10.	Wang, Jin: 2 articles (01/2021 - 01/2019)

Related Diseases

1.	Vomiting 08/01/1992 - "Only RS(+/-)-zacopride significantly reduced incidence of emesis. " 11/12/1991 - "Previous studies of the mechanism of zacopride-induced emesis in ferrets have concluded that it is mediated predominantly by an antagonist effect on 5-HT3 receptors although the possibility of a contribution from an agonist effect at 5-HT4 receptors was not excluded. " 01/17/1991 - "The involvement of 5-HT3 mechanisms is indicated by a correlation between zacopride and its enantiomers to cause and prevent emesis and their affinity at 5-HT3 binding sites. " 01/17/1991 - "Increasing doses of 0.01, 0.1, 1.0, 10.0 and 31.6 mg/kg of zacopride or its 2 enantiomers were each administered at hourly intervals to separate groups of animals until emesis occurred. " 06/01/1990 - "Zacopride, tested at several doses (0.003, 0.03 and 0.3 mg/kg), appeared to be more potent because it abolished emesis at 100-fold lower doses than did BMY25801 (3 mg/kg). "
2.	Neoplasms (Cancer) 02/01/1989 - "Zacopride was highly effective in inhibiting emesis due to a wide range of cancer chemotherapeutic agents, particularly cisplatin. " 07/01/1990 - "The location of 5-HT3 receptor recognition sites within the dorsal vagal complex may provide sites of action for zacopride and other 5-HT3 receptor antagonists to inhibit the emesis induced by cancer chemotherapeutic agents and x-radiation." 05/01/2006 - "The present study suggests that a combined 5-HT3-receptor antagonist/5-HT4-receptor agonist, like zacopride, may be useful against both acute and delayed emesis induced by cancer chemotherapy."
3.	Cardiac Arrhythmias (Arrythmia) 01/01/2017 - "Interestingly, zacopride eliminated the ex-vivo triggered arrhythmia in these muscles of non-failing and failing hearts in a concentration-dependent manner, with an effective IC50 in the range of 28-40μmol/L. " 01/01/2017 - "Therefore, the goal of the current study was to investigate the ex-vivo effects of zacopride on triggered arrhythmia and contractility in ventricular human myocardium in order to validate data that was solely obtained from animal models. " 01/01/2020 - "Effects of zacopride on cardiac arrhythmias were also explored experimentally both in vivo and in vitro. " 01/01/2017 - "However, in the absence of Ca2+ overload/arrhythmia, zacopride, albeit at high concentrations, decreases the force of contraction and increases the likelihood of occurrence of contractile alternans, which may predispose the heart to contractile dysfunction and/or arrhythmia. " 01/01/2017 - "Zacopride shows promising antiarrhythmic effects against triggered arrhythmia in human ventricular myocardium. "
4.	Seizures (Absence Seizure) 08/21/1992 - "5HT1c receptor antagonists (mianserin and cyproheptadine), 5-HT3 receptor antagonist (zacopride) and 5-HT4 receptor antagonist (ICS 205-930) increased the latency of audiogenic seizures and decreased the severity of convulsions in young (20-27 days old) DBA/2 mice. "
5.	Hypercapnia 02/01/2006 - "Zacopride decreased the hypercapnia, indicating an improvement in ventilation, whereas 8-OH-DPAT did not affect the hypercapnia and, therefore, did not improve ventilation. "

Related Drugs and Biologics

1.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
2.	Cisplatin (Platino)
3.	Granisetron (Kytril)
4.	5-HT4 Serotonin Receptors
5.	Ondansetron (Zofran)
6.	Antiemetics
7.	Benzamides
8.	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)
9.	Mianserin
10.	Cyproheptadine (Periactin)

Related Therapies and Procedures

1.	Radiotherapy
2.	Drug Therapy (Chemotherapy)
3.	Ischemic Postconditioning
4.	Vagotomy
5.	Intravenous Injections